» Articles » PMID: 39269596

Liquid-liquid Phase Separation-related Genes Associated with Prognosis, Tumor Microenvironment Characteristics, and Tumor Cell Features in Bladder Cancer

Overview
Specialty Oncology
Date 2024 Sep 13
PMID 39269596
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study aimed to explore the Liquid-liquid phase separation (LLPS)-related genes associated with the prognosis of bladder cancer (BCa) and assess the potential application of LLPS-related prognostic signature for predicting prognosis in BCa patients.

Methods: Clinical information and transcriptome data of BCa patients were extracted from the Cancer Genome Atlas-BLCA (TCGA-BLCA) database and the GSE13507 database. Furthermore, 108 BCa patients who received treatment at our institution were subjected to a retrospective analysis. The least absolute shrinkage and selection operator (LASSO) analysis was performed to develop an LLPS-related prognostic signature for BCa. The CCK8, wound healing and Transwell assays were performed.

Results: Based on 62 differentially expressed LLPS-related genes (DELRGs), three DELRGs were screened by LASSO analysis including kallikrein-related peptidase 5 (KLK5), monoacylglycerol O-acyltransferase 2 (MOGAT2) and S100 calcium-binding protein A7 (S100A7). Based on three DELRGs, a novel LLPS-related prognostic signature was constructed for individualized prognosis assessment. Kaplan-Meier curve analyses showed that LLPS-related prognostic signature was significantly correlated with overall survival (OS) of BCa. ROC analyses demonstrated the LLPS-related prognostic signature performed well in predicting the prognosis of BCa patients in the training group (the area under the curve (AUC) = 0.733), which was externally verified in the validation cohort 1 (AUC = 0.794) and validation cohort 2 (AUC = 0.766). Further experiments demonstrated that inhibiting KLK5 could affect the proliferation, migration, and invasion of BCa cells.

Conclusions: In this study, a novel LLPS-related prognostic signature was successfully developed and validated, demonstrating strong performance in predicting the prognosis of BCa patients.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Tran L, Xiao J, Agarwal N, Duex J, Theodorescu D . Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2020; 21(2):104-121. PMC: 10112195. DOI: 10.1038/s41568-020-00313-1. View

3.
Sjodahl G, Abrahamsson J, Holmsten K, Bernardo C, Chebil G, Eriksson P . Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2021; 81(5):523-532. DOI: 10.1016/j.eururo.2021.10.035. View

4.
Cao R, Yuan L, Ma B, Wang G, Qiu W, Tian Y . An EMT-related gene signature for the prognosis of human bladder cancer. J Cell Mol Med. 2019; 24(1):605-617. PMC: 6933372. DOI: 10.1111/jcmm.14767. View

5.
Zhu K, Xiaoqiang L, Deng W, Wang G, Fu B . Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer. Hum Genomics. 2021; 15(1):73. PMC: 8686253. DOI: 10.1186/s40246-021-00372-x. View